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Heparin, a commonly used anticoagulant drug, is a mixture
of highly sulfated polysaccharides with various molecular
weights (MWs). The unique sulfation pattern dictates the
anticoagulant activity of heparin. Commercial heparins
are categorized into three forms according to their average
MW: unfractionated heparin (UFH, MWavg 14,000), low-
MW heparin (LMWH, MWavg 3500–6500) and the synthetic
pentasaccharide (fondaparinux, MW 1508.3). UFH is isolated
from porcine intestine while LMWH is derived from UFH by
various methods of depolymerization, which generate a wide
range of oligosaccharide chain lengths. Different degradation
methods result in structurally distinct LMWH products, dis-
playing different pharmacological and pharmacokinetic prop-
erties. In this report, we utilized a chemoenzymatic method to
synthesize LMWH with the emphasis on controlling the size
distribution of the oligosaccharides. A tetrasaccharide primer
and a controlled enzyme-based polymerization were employed
to build a narrow size oligosaccharide backbone. The oligo-
saccharide backbones were further modified by a series of
sulfation and epimerization steps in order to obtain a full
anticoagulation activity. Determination of the anticoagulation
activity in vitro and ex vivo indicated that the synthetic
LMWH has higher potency than enoxaparin, a commercial
LMWH drug in clinical usage.
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weight heparin / sulfotransferases and oligosaccharides
Introduction
Heparin, a polysaccharide-based drug, has been well known for
its therapeutic anticoagulant effect for decades. Although the
development of novel anticoagulation agents is increasing,
heparin remains the drug of choice in several medical circum-
stances due to its rapid onset of action and relatively wide thera-
peutic window. Heparins are categorized into three forms
corresponding to their average molecular weights (MWs):
unfractionated heparin (UFH, MWavg 14,000), low-molecular-
weight heparin (LMWH, MWavg3500–6500) and the synthetic
pentasaccharide, fondaparinux (MW 1508.3) (Linhardt and Liu
2012). These heparins differ in their pharmacokinetic profiles,
providing different choices for cardiovascular treatments (Hirsh
and Raschke 2004). For instance, UFH is administered by intra-
venous injection. It has a rapid onset of action and is metabolized
by the liver at a fast clearance rate, which makes it useful in
patients undergoing surgery or renal hemodialysis (Heres et al.
2001). However, UFH requires routine monitoring due to its un-
predictable bioavailability. Moreover, 2–3% of patients adminis-
tered UFH are prone to develop a life-threatening adverse event
known as heparin-induced thrombocytopenia (HIT). Therefore,
UFH usage is generally restricted to hospitalized patients.
LMWH, on the other hand, has a number of advantages over
UFH including predictable bioavailability by subcutaneous
administration, longer half-life in plasma and lower incidences
of HIT and bleeding (Hirsh and Raschke 2004). All of these
advantages make LMWH useful for outpatient treatment and
prophylaxis of venous thromboembolism, acute myocardial
infarction and unstable angina. The advantage of synthetic penta-
saccharide is a decreased risk of HIT. However, it requires renal
excretion. Thus, the pentasacharide is not recommended for
patients with impaired renal function. Currently, LMWH is the
most commonly prescribed form of heparin (Merli and Groce
2010).
Heparin has the disaccharide-repeating unit of glucosamine
(GlcN) and hexuronic acid, including glucuronic acid (GlcA)
or iduronic acid (IdoA). Both GlcN and hexuronic acid residues
carry sulfo groups. Heparin inhibits coagulation by forming a
complex with antithrombin (AT). A unique pentasaccharide
domain in heparin, -GlcNAc6S-GlcA-GlcNS3S ± 6S-IdoA2S-
GlcNS6S-, plays a critical role in the binding to AT. When the
pentasaccharide binds to AT, a heparin-AT complex inactivates
several serine proteases such as factor Xa (FXa) and thrombin,
also known as factor IIa (FIIa). The inhibition of FXa and FIIa
activities prohibits the formation of a blood clot (Hirsh and
Raschke 2004).
UFH is extracted from porcine intestine and bovine lung,
whereas LMWH is derived from UFH by chemical and enzym-
atic depolymerization, resulting in oligosaccharide fragments
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(Linhardt and Gunay 1999). An investigation on LMWH
prepared from a contaminated UFH revealed that the current
manufacturing methods to prepare LMWH failed to eliminate
oversulfated chondroitin sulfate contamination (Zhang et al.
2008). The long and poorly regulated heparin supply chain has
raised concerns over the safety and reliability of animal-sourced
heparin and LMWH. Recently, a demand for a synthetic form
of LMWH has emerged. Although the synthetic pentasacchar-
ide is produced using a purely chemical approach (Petitou et al.
1991), it is extremely difficult to employ this method to prepare
LMWH because of the larger molecular size.
Commercially available LWMH has a broad range of oligosac-
charide size distribution with component MWs ranging from 3500
to 6500 leading to complex pharmacological/pharmacokinetic
effects. The polydispersity in the chain length may affect meta-
bolic clearance since short oligosaccharides require kidney clear-
ance while large polysaccharides are excreted by the liver (Pempe
et al. 2012). In addition, different approaches to manufacture
LMWH result in various product profiles across the LMWH
brands with distinct biochemical and pharmacological properties.
Three brands of LMWHs currently available in the United
States are obtained from different methods to depolymerize
UFH, resulting in different MW distributions. For example,
Enoxaparin (MWavg  4500) is produced from benzylation fol-
lowed by alkaline hydrolysis; Dalteparin (MWavg 6000) is
derived from controlled nitrous acid depolymerization; and
Tinzaparin (MWavg 6500) is prepared by controlled hepari-
nase digestion (Merli and Groce 2010). The US FDA indicates
that none of these product brands is interchangeable (Nightingale
1993). Furthermore, a structural characterization study on these
three LMWHs demonstrated that the depolymerization methods
potentially damage the pharmacophore of the LMWHs, reducing
the anticoagulant potency (Bisio et al. 2009).
Advancement in the understanding of heparin and heparan
sulfate (HS) biosynthetic pathway provides an opportunity to
develop a new method to manufacture LMWH using a chemoen-
zymatic approach. This method employs HS biosynthetic
enzymes, involving HS polymerases, an epimerase and various
sulfotransferases. It has been established that HS polymerases
synthesize a polysaccharide backbone consisting of -GlcA-
GlcNAc- disaccharide units. N-Deacetylase/N-sulfotransferase
is a bifunctional catalyst in which N-deacetylase removes an
acetyl group from GlcNAc resulting in a free amino group
(GlcNH2), whereas N-sulfotransferase (NST) adds a sulfate
group at a resultant GlcNH2 thereby yielding GlcNS (Duncan
et al. 2006). C5-epimerase (C5-epi) converts GlcA to IdoA.
Various sulfotransferases cofunctioning with a sulfo donor,
3′-phospho-adenosine-5′-phosphosulfate (PAPS), add sulfo
groups to their respective positions. 2-O-Sulfotransferase (2-OST)
adds sulfo groups at the 2-OH position of both GlcA and IdoA
while 6-O-sulfotransferase (6-OST) and 3-O-sulfotransferase
(3-OST) add sulfo groups at the 6-OH position and 3-OH of
GlcN residues, respectively (Peterson et al. 2009). An enzyme-
based approach has been developed as a desirable method to
produce a safer LMWH (Liu et al. 2010; Xu et al. 2011). The en-
zymatic method also offers an approach to rationally design a
heparin-like compound with improved pharmacological effects.
The enzymes regioselectively add monosaccharides and sulfo
groups, eliminating the need to introduce protecting/deprotecting
steps used in chemical synthesis, thus, significantly improving the
synthesis efficiency (Chappell and Liu 2012).
In this article, we report a chemoenzymatic approach to gener-
ate a narrow size distribution LMWH, namely “de novo
LMWH” (dnLMWH). We demonstrate a rapid procedure to syn-
thesize oligosaccharide backbones in a one-pot format. The use
of stoichiometrically controlled starting tetrasaccharide primer
and monosaccharide donors allowed us to modulate a degree of
oligomerization, yielding a narrow size distribution oligosacchar-
ide backbone. The resultant oligosaccharide backbones were
characterized and identified by strong anion-exchange high-
performance liquid chromatography (SAX-HPLC) and electro-
spray ionization mass spectrometry (ESI-MS). We utilized a
series of HS sulfotransferases to install an AT-binding pentasac-
charide domain within the synthetic backbones. The in vivo and
ex vivo anticoagulation activity of dnLMWH was determined.
Our data suggest that a carefully designed narrow size distribu-
tion LMWH has a high potency for anticoagulation activity.
Results
Controlling the degree of backbone oligomerization
We previously reported a chemoenzymatic method to synthesize
oligosaccharide backbones by sequential addition of monosac-
charide residues (Xu et al. 2012). Although this synthetic
method produces a homogeneous oligosaccharide backbone, the
method requires about 14 days for preparing a single dodecasac-
charide starting from a disaccharide. Here, we developed a
one-pot chemoenzymatic synthesis capable of producing the
dodecasaccharides, within 2 days. In order to build the oligosac-
charide backbone carrying a (-GlcNAc-GlcA-) repeating unit in a
one-pot format, a glycosyltransferase capable of transferring
monosaccharide donors, uridine 5′-diphosphate (UDP)-GlcNAc
and UDP-GlcA, is preferable. A heparosan synthase from bacteria
Pasteurella multocida (PmHS2), a bifunctional polymerase
capable of transferring both UDP-GlcNAc and UDP-GlcA, was
chosen for this synthesis (Sismey-Ragatz et al. 2007; Chavaroche
et al. 2010). Moreover, PmHS2 surpasses its substrate specificity
in recognizing certain unnatural UDP-GlcNs (Otto et al. 2012).
Therefore, PmHS2 meets our needs for a one-pot synthesis
(Sismey-Ragatz et al. 2007).
In order to control the size of the product in a one-pot reaction
format, we examined four different oligosaccharide primers:
disaccharide, tetrasaccharide, hexasaccharide and octasaccharide
(the structures of the oligosaccharide primers are shown in
Supplementary data, Table S1). Generally, the components of the
one-pot synthesis consist of a starting saccharide primer,
UPD-GlcNAc, UDP-GlcA and PmHS2. The starting saccharide
primer can be as short as a disaccharide or it can be as long as an
octasaccharide. Since the MWavg of commercial LWMHs is in a
range of 3500–6500 Da corresponding to 8–20 monosaccharide
units, we aimed to synthesize 10–14 saccharide units for back-
bone oligosaccharides. We hypothesized that the size of the
products can be controlled by tuning the ratio between a starting
primer and the monosaccharide donors. For example, when tar-
geting 12 saccharide units and using a tetrasaccharide as a primer,
a molar ratio between the tetrasaccharide, UDP-GlcNAc and
UDP-GlcA should be kept at 1:4:4. To this end, UDP-Glc[3H]
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NAc was used to monitor the degree of polymerization because
the incorporation of the Glc[3H]NAc allowed tracing the distribu-
tion of the oligosaccharide backbones using gel filtration chroma-
tography. When a disaccharide primer was used, we observed that
the products migrated to polymers regardless of the ratio between
the disaccharide primer and the UDP sugars (Figure 1A, upper).
Unlike the disaccharide primer, different sizes of oligosaccharide
products were obtained when a tetrasaccharide primer was
employed (Figure 1A, lower). In particular, desired size oligosac-
charide products were obtained when the molar ratio of tetrasac-
charide:UDP-Glc[3H]NAc:UDP-GlcA was kept at 1:4:4. We
found that the hexasaccharide and the octasaccharide produced
the oligosaccharides in a similar pattern as observed for the tetra-
saccharide primer (Supplementary data, Figure S1). SAX-HPLC
was employed to analyze the size distribution of the oligosacchar-
ide backbones (Figure 1B), demonstrating the presence of
3H-labeled oligosaccharide backbones with different sizes.
Co-eluting nonradiolabeled oligosaccharides followed by
ESI-MS analysis confirmed the structures of the oligosaccharide
products (Supplementary data, Figure S2, Supplementary data,
Table S2). The oligosaccharide distribution analysis indicated that
the size of the oligosaccharide backbones was in the range of dp
8–16 (Figure 1C) where dp 10 (24.6%) and dp 12 (24.5%) are
major products (Figure 1C). The tetrasaccharide primer was
therefore selected as a primer for the preparation of LMWH in the
subsequent studies.
N-Sulfation of oligosaccharide backbones
Next, we used the one-pot format to prepare the oligosaccharides
with N-sulfation by preparing a backbone oligosaccharide with
-GlcNTFA-GlcA-, where the GlcNTFA represents N-trifluoroa-
cetyl GlcN. Replacing UDP-GlcNAc with UDP-NTFA in a
backbone synthetic step allowed us to prepare the backbone oli-
gosaccharides. A molar ratio between the tetrasaccharide primer,
UDP-GlcNTFA and UDP-GlcA, was selected to be 1:4:4 to
prepare the products. As expected, PmHS2 is also capable of in-
corporating the GlcNTFA residues into the backbones yielding
the (-GlcNTFA-GlcA-) repeating backbones. The (-GlcNTFA-
GlcA-) backbones were identified by ESI-MS, showing desired
product and partially detrifluoroacetylated products due to the
fact that trifluoroacetyl group is labile under basic conditions
(Figure 2, Table I). Because the (-GlcNTFA-GlcA-) repeating
backbones were eventually subjected to complete alkaline detri-
fluoroacetylation resulting in the -GlcNH2-GlcA-) repeating
backbones, the partial detrifluoroacetylation would not affect the
subsequent synthesis. The resultant (-GlcNH2-GlcA-) backbones
were further treated with NSTand PAPS. ESI-MS analysis of the
Fig. 1. Optimization of a primer and a molar ratio in a one-pot reaction. A disaccharide (A, upper) and a tetrasaccharide (A, lower) were used as primers in a
one-pot synthesis. The oligosaccharide products were obtained by gel filtration chromatography. The ratios between the primers, UDP-[3H]GlcNAc and UDP-GlcA
are shown (1:1:1 = grey-solid, 1:2:2 = grey-dash, 1:4:4 = black-solid, 1:10:10 = black-dot). V0, void volume and Vt, total volume. The
3H-oligosaccharide
products obtained from a reaction when the tetrasaccharide was used at 1:4:4 were pooled. A size distribution of the 3H-labeled products was analyzed by strong
anion-exchange HPLC. The nonradiolabeled oligosaccharides were co-eluted and identified by ESI-MS analysis; dp, degree of polymerization (B).
The distribution of the oligosaccharide chain length was estimated as a percentage (C).
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backbones resolved from Bio-Gel P-2 after N-sulfation step
indicated that the (-GlcNS-GlcA-) repeating backbones were
produced (Supplementary data, Figure S3, Supplementary data,
Table S3).
Placing AT-binding site inside the oligosaccharide backbones
by epimerization and O-sulfation modification
Heparin displays its anticoagulant activity by binding to AT
through the unique pentasaccharide region (Hirsh and Raschke
2004). An important step in heparin synthesis is to properly
install the AT-binding site within the oligosaccharide backbones.
Structural analysis of heparin revealed that the AT-binding site is
randomly distributed along the polysaccharide chain (Oscarsson
et al. 1989) providing flexibility for placing the AT-binding
region. We found that by placing a GlcNAc residue at the
nonreducing end of N-sulfo oligosaccharide backbones, the pen-
tasaccharide motif could be readily produced by the latter epimer-
ization and sequential sulfo modifications (Sheng et al. 2012). An
installation of the GlcNAc residue directs the irreversible catalytic
mode of C5-epi such that GlcA at residue D is irreversibly con-
verted to IdoA (Figure 3). The GlcNAc elongation was catalyzed
by an N-acetyl glucosaminyl transferase of Escherichia coli K5
strain (KfiA) as described elsewhere (Chen et al. 2006). We
confirmed the completion of GlcNAc elongation by ESI-MS ana-
lysis (Supplementary data, Figure S4 and Table S4). Once the
GlcNAc elongation was achieved, we used recombinant C5-epi
for epimerization as well as a series of HS sulfotransferases for
O-sulfo addition. The presence of the GlcA at residue B controls
a specific addition of a sulfo group at residue C but not residue
E by 3-OST-1 (Moon et al. 2012). The O-sulfated products
were purified by diethylaminoethyl (DEAE) anion-exchange
Fig. 2.MS analysis of the NTFA backbones. ESI (negative mode)-mass spectrum analysis of oligosaccharide backbones when a ratio between a tetrasaccharide
primer, UDP-GlcN-TFA and UDP-GlcAwas kept at 1:4:4. Line corresponds to the oligosaccharide chain length (dp8 = octasaccharide, dp10 = decasaccharide,
dp12 = dodecasaccahride, dp14 = tetradecasaccharide, dp16 = hexadecasaccharide, dp18 = octadecasaccharide). Subnumbered molecular species indicated multiply
charged and detrifluoroacetylated species, respectively. For example, dp 12.2.3 (MW 1081.4) is a double charge dodecasaccharide with the loss of three fluoroacetyl
groups (see Table I).
Table I. ESI-MS analysis of (-GlcA-GlcNTFA-) backbones
Name Abbreviated structure Mr
Calculated Measured
Octasaccharide (dp 8) (GlcA-GlcNTFA)2-GlcA-GlcNAc-GlcA-AnMan 1586.2 1586.5 ± 0.6
Decasaccharide (dp 10) (GlcA-GlcNTFA)3-GlcA-GlcNAc-GlcA-AnMan 2019.5 2019.3 ± 1.3
Dodecasaccharide (dp 12) (GlcA-GlcNTFA)4-GlcA-GlcNAc-GlcA-AnMan 2452.7 2453.2 ± 0.8
Tetradecasaccharide (dp 14) (GlcA-GlcNTFA)5-GlcA-GlcNAc-GlcA-AnMan 2886.0 2885.1 ± 1.2
Hexadecasaccharide (dp 16) (GlcA-GlcNTFA)6-GlcA-GlcNAc-GlcA-AnMan 3319.3 3318.9 ± 0.5
Octadecasaccharide (dp 18) (GlcA-GlcNTFA)7-GlcA-GlcNAc-GlcA-AnMan 3752.6 3752.2 ± 1.1
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chromatography. We ensured the completion of each O-sulfation
by performing a small-scale reaction using PAP35S to monitor the
reaction.
It is important to demonstrate that one-pot synthesis can be
performed in a reproducible way to produce narrow size distribu-
tion of the oligosaccharide backbones. We performed three indi-
vidual synthetic batches. ESI-MS analyses confirmed that the
(-GlcNTFA-GlcA-) and the (-GlcNH2-GlcA-) backbones are
similar across the three batches. The (-GlcNH2-GlcA-) backbones
were treated with NST and PAP35S yielding (-GlcN35S-GlcA-)
backbones. The backbones were purified and subjected to
DEAE-HPLC analysis. The result shows that all three batches
have similar oligosaccharide distributions (Figure 4A). We also
tested the oligosaccharide distribution by conducting a [3H]
GlcNAc elongation of the (-GlcNS-GlcA-) backbones. The
3H-labeled backbones showed similar results (Figure 4B).
Structural characterization of dnLMWH
After the modifications with C5-epi and O-sulfotransferases,
ESI-MS analysis for dnLMWH products was difficult due to
the structural complexity resulting from incomplete O-sulfation
and epimerization. Instead, disaccharide analysis was used to
characterize the structures of the product. To this end, two
approaches for cleaving dnLMWH into disaccharide units were
employed: an enzymatic digestion and a chemical degradation.
Heparin lyases recognize saccharide units carrying sulfo groups
at the 2-O- and 6-O-positions. However, oligosaccharides car-
rying 3-O-sulfo groups are resistant to heparin lyases (Shriver
et al. 2000), thus requiring a nitrous acid degradation (Shively
and Conrad 1976). 35S-Label was also introduced to facilitate
the disaccharide analysis. To analyze the 35S-labeled-2-O- and
6-O-oligosaccharides, we treated the compound with three
heparin lyases, I, II and III. We observed that the majority of
GlcNS residues carried 6-O-sulfo groups (Supplementary data,
Figure S5A). Furthermore, the content of the IdoA2S found in
the corresponding IdoA2S-GlcNS6S unit suggested that the
product has similar structure to heparin (Supplementary data,
Figure S5B). A critical modification that drives the binding
of a pentasaccharide to AT is a 3-O-sulfo modification at
GlcNS ± 6S within the pentasaccharide (Duncan et al. 2004).
We determined AT-binding activity of dnLMWH since it is an
initial step prior to FXa inhibition. Moreover, AT-binding activ-
ity also suggested the presence of 3-O-sulfo modification on
dnLMWH (Figure 5A). The knowledge of substrate specificity
suggests that 3-OST-1 inserts a sulfo group at GlcNS6S that
is adjacent to the GlcA at the reducing end (-GlcA-
GlcNS3S* ± 6S-) (Liu et al. 1996; Moon et al. 2012). A disac-
charide, GlcA-AnMan3S6S, indicated the presence of a
3-O-sulfo group on dnLMWH (Figure 5B); however, the level
of 3-O-sulfated disaccharide is higher than expected. Although
dnLMWH was designed for a placement of a 3-O-sulfo group
only at the AT-binding site, it was expected that a mixture of
GlcA-GlcNS6S residue outside the AT-binding region, resulted
from incomplete C5-epimerization and 2-O-sulfation, might be
subjected to a 3-O-sulfo modification. Further, the results are
largely consistent with our previous publication (Xu et al.
2012). In this study, a fully sulfated 15-mer compound that was
prepared using similar approaches contained 26% 3-O-sulfated
disaccharide (GlcA-AnMan3S6S).
Determination of in vitro and ex vivo anti-FXa activity
Heparin achieves its anticoagulant activity by binding to AT, and
the complex of heparin and AT inhibits the activities of FXa and
FIIa. Although heparin has both anti-FXa and anti-FIIa activities
Fig. 3. Schematic synthesis of dnLMWH. A scheme illustrates the synthetic steps starting from an incubation of a tetrasaccharide primer with UDP-GlcN-TFA and
UDP-GlcA at a 1:4:4 molar ratio (upper panel). The (-GlcNTFA-GlcA-) repeating backbones were subjected to detrifluoroacetylation and N-sulfation. The GlcNAc
elongation aided in an installation of the AT-binding site. Sequential modification by epimerization and 2-O-, 6-O- and 3-O-sulfation were required to achieve
dnLMWH (lower panel).
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(Petitou et al. 1999), LMWH displays higher activity toward
FXa than toward FIIa. Previously, we demonstrated that only
those oligosaccharides >19 saccharide residues have anti-FIIa ac-
tivity (Xu et al. 2012). Since 10 and 12 saccharide units are the
major products found in dnLMWH, dnLMWH should exhibit
only anti-FXa activity. Thus, we determined the anti-Xa activity
using a chromogenic substrate. Enoxaparin was used to compare
the activity since its MWavg is similar to dnLMWH. Enoxaparin
or dnLWMH was incubated with human AT allowing the
AT-dnLMWH complex to inhibit FXa. Indeed, dnLMWH (IC50
40 ng/mL) showed superior anti-FXa activity in comparison
with enoxaparin (IC50 96 ng/mL) (Figure 6A). Next, we
confirmed that dnLMWH possesses a high potency of anti-FXa
activity and anticipated pharmacokinetic profiles when adminis-
tered to mice. Enoxaparin and dnLWMH were given subcutane-
ously to the mice at 1.5 mg/kg while phosphate buffer saline
(PBS)-treated mice were used as a control group. As demon-
strated in Figure 6B, dnLMWH exhibits significantly higher
anti-FXa activity compared with enoxaparin up to 2 h after
injection, with a maximum effect observed 30 min after injec-
tion. Both the in vitro and ex vivo experiments indicate that
dnLMWH displays stronger anticoagulant activity than a com-
mercially available LMWH.
Discussion
LMWH has been used in cardiovascular disorders for almost 30
years. To date, LMWH is clinically favored over UFH due to its
superior pharmacokinetic properties. However, among commer-
cial brands, LMWHs differ in polysaccharide size distribution
and the active pentasaccharide content (Bisio et al. 2009). The
polydispersity of LMWH affects the duration of action, drug
potency and clinical safety (Fareed et al. 1998). Therefore,
controlling LMWH size distribution is essential for more predict-
able pharmacological responses. While the current research on
Fig. 4. Reproducibility of the synthesis of N-sulfated backbones using one-pot synthesis format. Reproducibility of oligosaccharide size distribution by the one-pot
method was assessed by three individual batch syntheses (1 = upper; 2 = middle; 3 = lower panels). The similarity of the distribution profiles between each batch
indicates the reproducibility of the method. (A) 35S-radioactivity. In the first test, the (-GlcNTFA-GlcA-) backbones from each batch were subjected to N-sulfation by
using PAP35S. (B) 3H-radioactivity. In the second test, the (-GlcNS-GlcA-) backbones from each batch were subjected to Glc[3H]NAc elongation. The resultant 35S- and
3H-labeled oligosaccharides were resolved by anion-exchange (DEAE)-HPLC (A and B, respectively). PAPS, 3′-phosphoadenosine-5′-phosphosulfate, a sulfo donor.
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improving LMWH production methods is moving forward, most
of the approaches remain focused on obtaining oligosaccharide
fragments from UFH derived from animals. Thus, the develop-
ment of a novel approach that avoids the use of animal sources
and obtains a high-potency LMWH is beneficial for clinical
applications.
Although a homogenous oligosaccharide product is the ultim-
ate goal of LMWH production, to date, a chemical approach
has reached its limit due to the complex structure of LMWH. In
this paper, we demonstrated a quick chemoenzymatic method to
produce a narrow size distribution oligosaccharide backbone,
providing a suitable platform to design an LMWH with high
anticoagulant activity. We demonstrated that the degree of
polymerization could be controlled by selecting an appropriate
starting primer and by tuning the molar ratio of the primer and
the UDP sugars. The controlled one-pot oligosaccharide synthe-
sis using a bifunctional polymerase is a feasible approach to
produce restricted size distribution oligosaccharides. Heparosan
synthases from P. multocida were characterized into two iso-
forms: PmHS1 and PmHS2. Although PmHS1 was found to
promote a formation of a monodisperse polysaccharide, the poly-
saccharide products are in a high-MW range (Sismey-Ragatz
et al. 2007; Chavaroche et al. 2011). PmHS2, on the other hand,
produces a short-length oligosaccharide that is the targeted size
for LMWH production. In addition, PmHS1 lacks the capability
to incorporate an unnatural sugar, e.g., UDP-GlcN-TFA (Sismey-
Ragatz et al. 2007). Therefore, PmHS2 served as a suitable glyco-
syltransferase in this synthetic fashion. In a one-pot synthetic
method, the presence of a starting primer potentially bypasses
the initiation phase of an elongation process by PmHS2, such that
the UDP-sugar donors are successively transferred to the acceptor
primer. A tetrasaccharide primer contributing to oligosaccharides
instead of polysaccharides indicated that a longer saccharide unit
is at least required to occupy an acceptor site on PmHS2. We
found that this hypothesis is consistent with several reports (Jing
and DeAngelis 2004; Sismey-Ragatz et al. 2007; Otto et al.
Fig. 6. Determination of anti-FXa activity of dnLMWH. (A) In vitro anti-FXa activity determined by the rate of an increase in absorbance of a chromogenic substrate
of human FXa at the wavelength of 405 nm (an average from three independent experiments). The IC50 was determined relatively to FXa activity when the activity
without drug is defined as 100%. Compounds are shown: HS (triangle), enoxaparin (square) and dnLMWH (circle). (B) Ex vivo anti-FXa activity of the plasma
collected from the mice injected subcutaneously with dnLMWH (red) or enoxaparin (blue) (**P < 0.05 and **** P < 0.0001; n = 3–5 mice for each time point and
treatment).
Fig. 5. Investigation of 3-O-sulfation on dnLMWH. The AT-binding assay
requires a radiolabeled material for a measurement of percent-binding activity
to AT (A). The 35S-labeled at 3-O-postion of HS was used as a positive control
(1). 35S-labeled only at 2-O- and 6-O- positions of dnLMWHwas used as a
negative control (2). 35S-labeled at 3-O-position of dnLMWHwas shown in
(3). The data presented represent the average of three independent
determinations ± SD. Oligosaccharides obtained after N-sulfation and GlcNAc
elongation steps were 35S-labeled at 2-O-sulfo and 6-O-sulfo and 3-O-sulfo
positions. A presence of GlcA-AnManNS3S6S was analyzed by nitrous acid
degradation. The resultant disaccharides were analyzed by reverse-phase
ion-pairing HPLC. The distribution of the disaccharide units was estimated as a
percentage. The percentages of disaccharide are presented as mean ± SD (B).
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2012). A previous study showed that PmHS2 is likely to catalyze
a new chain initiation preferably using UDP-GlcNAc as an
acceptor resulting in the generation of endogenous sugar back-
bones, e.g., GlcA-GlcNAc-UDP (Chavaroche et al. 2011).
However, we were unable to observe the endogenous products
generated. We found that only even numbered-oligosaccharide
products were present. This observation is expected given the fact
that PmHS2 catalyzes the transfer of UDP-GlcA at a higher rate
than UDP-GlcNAc (Chavaroche et al. 2011; Otto et al. 2012).
Apart from offering an expedited method to produce oligo-
saccharide backbones, a one-pot synthesis is an easy approach
for installation of an AT-binding site. After a backbone synthet-
ic step, the anticoagulation activity can be achieved by five add-
itional modification steps. The method is clearly reproducible
in providing products with consistency in size distribution of
the oligosaccharide backbones. The anti-Xa activity, demon-
strated in vitro and ex vivo, indicated that dnLMWH has a
greater anti-Xa potency than Enoxaparin. The minimal hetero-
geneity as well as the increased proportion of active pentasac-
charide permitted a high potency with respect to anti-Xa
activity. It is known that 3-O-sulfated decasaccharide or larger
are metabolized by the liver (Pempe et al. 2012). dnLMWH
might be beneficial in patients in whom synthetic pentasacchar-
ides are contraindicated due to renal insufficiency.
Materials and methods
Preparation of PmHs2 and other HS biosynthetic enzymes
PmHS2 was expressed as an N-terminal fusion to His6 using
PET-15b vector (Novagen) (Sismey-Ragatz et al. 2007). The
expression of PmHS2 was carried out in BL21 star (DE3) cells
(Invitrogen) coexpressing bacteria chaperone proteins, GroEL
and GroES. A total of seven enzymes were used for the synthe-
sis, including N-acetyl-D-glucosaminyl transferase (KfiA),
NST, C5-epi, 2-O-sulfotransferase (2-OST), 6-OST-1/3 and
3-OST-1. All enzymes were expressed in E. coli and purified
by appropriate affinity chromatography as described previously
(Liu et al. 2010).
Preparation of monosaccharide donors and a sulfate donor
UDP-GlcNAc and UDP-GlcA were purchased from Sigma–
Aldrich while UDP-N-trifluoroacetylglucosamine (GlcNTFA)
was synthesized by a chemoenzymatic approach as previously
described (Liu et al. 2010). In brief, GlcNTFA was generated
from a reaction between GlcNH2-1-phosphate (Sigma–Aldrich)
and S-ethyl trifluorothioacetate (Sigma–Aldrich). The resultant
GlcNTFAwas converted to GlcNTFA 1-phosphate using N-acet-
ylhexosamine 1-kinase. The plasmid expressing N-acetylhexosa-
mine 1-kinase was a gift from Prof. Peng Wang, and the
expression of the enzyme was carried out in E. coli as reported
(Zhao et al. 2010). A coupling of UTP and GlcNTFA 1-phosphate
resulting in UDP-GlcNTFAwas completed by GlcN-1-phosphate
acetyltransferase/N-acetylglucosamine-1-phosphate uridyltransfer-
ase (GlmU). UDP-[N-[3H]acetyl]GlcNAc was synthesized by an
enzymatic approach as previously described (Chen et al. 2006).
A sulfo donor, PAPS, was prepared starting from Na2SO4 and
ATP (Sigma–Aldrich) using ATP sulfurylase and adenosine
phosphokinase (Zhou et al. 2011).
Saccharide primer preparations
A disaccharide precursor, 2,5-anhydromannitol (GlcA-AnMan)
was obtained from a chemical depolymerization of heparosan
K5 polysaccharide as previously described (O’Leary et al.
2013). A tetrasaccharide primer was initiated from a reaction
mixture of GlcA-AnMan (5 mg), UDP-GlcNAc (0.5 mM) and
KfiA (20 μg/mL) in a 30 mL buffer containing 25 mM MnCl2
in 50 mM Tris–HCl (pH7.5) at 37°C overnight to obtain a tri-
saccharide (GlcNAc-GlcA-AnMan). The resultant trisaccharide
was purified using 0.75 × 200 mm Bio-Gel P-2 (Bio-Rad,
Hercules, CA) that was equilibrated with 0.1 M ammonium bi-
carbonate (NH4HCO3) at a flow rate of 4 mL/h. The fractions
were directly subjected to ESI-MS analysis and the fractions
containing trisaccharide were pooled. The trisaccharide dis-
solved in NH4HCO3 was then dried (Centrivap, LABCONCO,
Kansas City, MO). To elongate a trisaccharide to a tetrasacchar-
ide, the trisaccharide was reconstituted in water and incubated
with UDP-GlcA (0.5 mM) PmHS2 (20 µg/mL) in a buffer con-
taining 25 mM MnCl2 in 50 mM Tris–HCl (pH 7.5) at 37°C
overnight. The resultant tetrasaccharide (GlcA-GlcNAc-
GlcA-AnMan) was purified and pooled as described above.
Other oligosaccharide primers were synthesized by sequential
elongation of UDP sugars to the tetrasaccharide to obtain a
hexasaccharide (GlcA-GlcNAc-GlcA-GlcNAc-GlcA-AnMan)
and an octasaccharide (GlcA-GlcNAc-GlcA-GlcNAc-GlcA-
GlcNAc-GlcA-AnMan).
Optimization of a one-pot enzymatic reaction using
radiolabeled UDP-Glc[3H]NAc
All PmHS2 catalyzed reactions were performed at room tem-
perature (RT) overnight in a 200 μL buffer containing 50 mM
Tris, pH 7.5 containing 25 mM MnCl2. An individual reaction
mixture consisted of various molar ratios (1:1:1, 1:2:2, 1:4:4
and 1:10:10) between saccharide primers, UDP-GlcNAC and
UDP-GlcA. UDP-[3H]GlcNAc (6.7 × 104 cpm/μL) was mixed
with UDP-GlcNAc prior adding to the reaction. The oligosac-
charide products were purified by 0.75 × 200 cm Bio-Gel P-10
column (Bio-Rad, Hercules, CA) which was equilibrated with a
buffer containing 20 mM Tris–HCl buffer (pH 7.5) in 1 M
NaCl. The 3H-labeled-oligosaccharide fractions were identified
(Packard Tri-Carb 2500 TR) and pooled. Then, it was dialyzed
against H2O and subjected to SAX-HPLC analysis as described
below.
SAX-HPLC analysis
The distribution of oligosaccharide backbones was demonstrated
using an SAX-HPLC (5 μM × 80 Å × 250 mm × 4.6 mm,
Phenomenex, Torrance, CA). The dialyzed 3H-radiolabeled
oligosaccharide backbones were eluted with a linear gradient
of 0–100% 0.5 M NaCl (pH 3) at a flow rate of 0.5 mL/min in
150 min.
Synthesis of (-GlcA-GlcNTFA-) oligosaccharide backbones
The oligosaccharide backbone synthesis was carried out corre-
sponding to the optimal condition described above. Briefly,
a mixture of the tetrasaccharide primer (0.35 mM), UDP-
GlcNTFA (1.4 mM) and UDP-GlcA (1.4 mM) were incubated
at 1:4:4 molar ratio with PmHS2 (30 μg/mL) at RT overnight.
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The reaction was purified using Bio-Gel P-2. Then, the result-
ant (-GlcA-GlcNTFA-) repeating backbones were subjected to
ESI-MS analysis and pooled. The backbones dissolved in
NH4HCO3 were dried prior to the N-sulfation step.
N-Sulfation of oligosaccharide backbones
N-Sulfation was initiated by detrifluoroacetylation of the
GlcN-TFA residue (de-N-TFA). The de-N-TFA step required
overnight incubation of a reagent containing 2:2:1 (v/v/v) H2O,
CH3OH and (C2H5)3N at 50°C in 50 mL. The reaction mixture
was dried and reconstituted in water to obtain the resultant
-(GlcNH2-GlcA)- backbones. The addition of sulfo groups at the
GlcNH2 residue was carried out by incubation of -(GlcNH2-
GlcA)- backbones with NST (10 μg/mL) and PAPS (500 μM) at
37°C overnight in a buffer containing 50 mM 2-(N-morpholino
ethane sulfuric acid) (MES) (pH 7.4) in a total volume of 40 mL.
MS analysis of oligosaccharide backbones
All MS analyses were carried out in a negative electrospray ion-
ization mode using a Thermo Scientific LCQ-Deca system. The
electrospray source was set to 5 kV and 275°C and a syringe
pump (Harvard Apparatus) was used to inject the samples via
direct infusion (35 μL/min). The oligosaccharide backbones
(5 μL) purified from a Bio-Gel P-2 column in each synthetic step
were directly diluted in 200 μL of 8:2 MeOH:H2O. The MS data
were acquired and processed using Xcalibur 13 software.
Placement of AT-binding site at the nonreducing end
of the (-GlcA-GlcNS-) backbones
To create the AT-binding site within the oligosaccharide back-
bones, GlcNAc elongation, C5-epimerization, 2-O-, 6-O- and
3-O-sulfation modifications were required. The GlcNAc elong-
ation was completed by KfiA as described under “Saccharide
Primer Preparations”. The GlcNAc-(GlcA-GlcNS)- backbones
were incubated in a reaction mixture containing 50 mM MES
(pH 7.4) C5-epi (20 μg/mL) and 2 mM CaCl2 in a total volume
of 40 mL. After incubation for 30 min at 37°C, 2-OST (20 μg/
mL) and 500 μM PAPS were added, and the reaction was incu-
bated overnight at 37°C. The products were purified using a
DEAE column as described previously (Xu et al. 2012). The re-
sultant 2-O-sulfated products were dialyzed against water prior
to the next sulfation step. For 6-O-sulfation, the substrate was
incubated overnight at 37°C in a reaction mixture containing
50 mM MES (pH 7.0) and 500 μM PAPS in the presence of
6-OST-1 (20 μg/mL) and 6-OST-3 (20 μg/mL) in a total
volume of 40 mL. For 3-O-sulfation, the substrate was incu-
bated with 3-OST-1 (10 μg/mL) and 500 μM PAPS at 37°C
overnight in a reaction mixture containing, 10 mM MnCl2,
5 mMMgCl2 and 50 mMMES in a total volume of 30 mL.
Disaccharide analysis of dnLMWH
The oligosaccharide backbones carrying 35S-sulfo groups at
2-O- and 6-O-positions were exposed to heparin lyase I, II and
III (0.1 mg/mL each) in 200 μL of 50 mM sodium phosphate
(pH 7) at 37°C. The reaction was terminated by boiling at 100°
C for 5 min and was desalted by 0.75 × 200 mm Bio-Gel P-2
gel. The 3-O-sulfated backbones were deacetylated and
degraded with nitrous acid at pH 4.5 and then at pH 1.5,
followed by reduction with sodium borohydride as described
by Shively and Conrad (Shively and Conrad 1976). The result-
ant 35S-labeled disaccharides were resolved using a C18
reverse-phase column (0.46 × 25 cm; Vydac) under reverse-
phase ion-pairing HPLC conditions (Duncan et al. 2006). The
identities of the disaccharides were determined by co-elution
with the appropriate 35S-labeled disaccharide standards.
Determination of AT-binding activity
Approximately 1 × 104 cpm of each oligosaccharide were incu-
bated with 5 μg of human AT in 50 μL of binding buffer con-
taining 10 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM Mn2+,
1 mM Mg2+,1 mM Ca2+, 10 μM dextran sulfate, 0.0004%
Triton X-100 and 0.02% sodium azide for 30 min at RT, re-
spectively. Concanavalin A-Sepharose gel (Sigma, 200 μL of
1:1 slurry) was then added, and the reaction was shaken at RT
for 2 h. The beads were then washed three times with 1 mL of
binding buffer, and the amount of 35S-labeled radioactivity was
determined by scintillation counting.
In vitro anti-FXa activity
An assay was carried out based on a published method (Chen
et al. 2007). In brief, human AT (Cutter Biological) was diluted
with PBS containing 1 mg/mL bovine serum albumin (BSA) to
give a stock solution at a concentration of 0.4 μM. Human FXa
(Enzyme Research Laboratories, South Bend, IN) was diluted
with PBS containing 1 mg/mL bovine serum albumin at a con-
centration of 80 nM. A chromogenic substrate for FXa, S-2765
(Diapharma, West Chester, OH) was dissolved in water at a con-
centration of 1 mM. HS from bovine kidney, enoxaparin (local
pharmacy) and dnLMWH were dissolved in PBS at various
concentrations (5–100 ng/μL). The assay was initiated by incu-
bation of the drugs with 80 µL human AT stock solution at RT
for 2 min. Then 10 μL of FXa was added. After incubation at
RT for 4 min, 30 μL of S-2765 was added. The absorbance at
405 nm was continuously measured for 5 min. The absorbance
values were plotted against the reaction time. The initial reac-
tion rates as a function of concentration were used to calculate
IC50 values. The activity without drug was defined as 100%.
Ex vivo anti-FXa activity
The Institutional Animal Care and Use Committee at UNC
approved all animal procedures. Female C57BL/6J mice weigh-
ing 20–25 g were purchased from Jackson Laboratory (Bar
Harbor, ME). Under anesthesia by isoflurane (2% in oxygen),
PBS, enoxaparin (1.5 mg/kg) and dnLMWH (1.5 mg/kg) were
subcutaneously administered to the mice. After 30 min, 1, 2, 4
and 8 h, mice were anesthetized and a midline laparotomy was
performed. Blood (300–500 μL) from inferior vena cava was
collected into syringes containing 3.8% sodium citrate solution
at the final blood to sodium citrate volume 9:1. The blood
samples were centrifuged at 4000 × g at 4°C for 15 min to
obtain mouse plasma. The plasma was frozen at −80°C until
the analyses were performed. The plasma containing the drug
at each time point was used to determine FXa activity. The FXa
activity assay was carried out similar to the in vitro experiment.
Briefly, the assay mixture consisted of PBS (80 μL), mouse
plasma (10 μL) and 80 nM human FXa (10 μL) was incubated
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at RT. After 4 min, S-2765 (30 μL) was then added. FXa activ-
ity was calculated as a percent when PBS mice were defined as
100%.
Statistical analysis
All statistical analyses were performed using Sigma Plot
Software (version 11; Systat Software, Inc., San Jose, CA).
Data are represented as mean ± SEM. For two-group compari-
son of continuous data, two-tailed Student’s t-test was used. A
P-value of ≤0.05 was regarded as significant.
Supplementary data
Supplementary data for this article is available online at http://
glycob.oxfordjournals.org/.
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AT, antithrombin; C5-epi, C5-epimerase; DEAE, diethylami-
noethyl; dp, degree of polymerization; FXa, factor Xa; FIIa,
factor IIa; GlcA, glucuronic acid; GlcN, glucosamine; GlcNAc,
N-acetylglucosamine; GlcNS6S, N,6-O-sulfo glucosamine;
GlcNS3S6S, N,3,6-O-sulfo glucosamine; Glc-NTFA, N-trifluor-
oacetylglucosamine; HIT, heparin-induced thrombocytopenia;
HPLC, high-performance liquid chromatography; HS, heparan
sulfate; IdoA, iduronic acid; KfiA, N-acetyl glucosaminyl trans-
ferase of E. coli K5 strain; LMWH, low-molecular-weight
heparin; MES, 2-(N-morpholino ethane sulfuric acid); NST,
N-sulfotransferase; PAPS, 3′-phosphoadenosine-5′-phosphosul-
fate; PBS, phosphate buffer saline; PmHS2, Pasteurella
multocida heparosan synthase 2; RT, room temperature; SAX,
strong anion exchange; UDP, uridine 5′-diphosphate; UFH,
unfractionated heparin; 2-OST, 2-O-sulfotransferase; 3-OST-1,
3-O-sulfotransferase isoform 1; 6-OST-1/3, 6-O-sulfotransferase
isoform 1/isoform 3.
References
Bisio A, Vecchietti D, Citterio L, Guerrini M, Raman R, Bertini S, Eisele G,
Naggi A, Sasisekharan R, Torri G. 2009. Structural features of low-
molecular-weight heparins affecting their affinity to antithrombin. Thromb
Haemost. 102:865–873.
Chappell EP, Liu J. 2012. Use of biosynthetic enzymes in heparin and heparan
sulfate synthesis. Bioorg Med Chem. 21:4786–4792.
Chavaroche AAE, Springer J, Kooy F, Boeriu C, Eggink G. 2010. In vitro syn-
thesis of heparosan using recombinant Pasteurella multocida heparosan syn-
thase PmHS2. Appl Microbiol Biotech. 85:1881–1891.
Chavaroche AAE, van den Broek LAM, Springer J, Boeriu C, Eggink G. 2011.
Analysis of the polymerization initiation and activity of Pasteurella multo-
cida Heparosan synthase PmHS2, an enzyme with glycosyltransferase and
UDP-sugar hydrolase activity. J Biol Chem. 286:1777–1785.
Chen M, Bridges A, Liu J. 2006. Determination of the substrate specificities of
N-acetyl-d-glucosaminyltransferase. Biochemistry. 45:12358–12365.
Chen J, Jones C, Liu J. 2007. Using an enzymatic combinatorial approach
to identify anticoagulant heparan sulfate structures. Chem Biol. 14:986–983.
Duncan MB, Chen JH, Krise JP, Liu J. 2004. The biosynthesis of anticoagulant
heparan sulfate by the heparan sulfate 3-O-sulfotransferase isoform 5.
Biochim Biophys Acta. 1671:34–43.
Duncan MB, Liu M, Fox C, Liu J. 2006. Characterization of the N-deacetylase
domain from the heparan sulfate N-deacetylase/N-sulfotransferase 2.
Biochem Biophy Res Commun. 339:1232–1237.
Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. 1998.
Low-molecular-weight heparins: Pharmacologic profile and product differ-
entiation. Am J Cardiol. 82:3L–10L.
Heres EK, Speight K, Benckart D, Marquez J, Gravlee GP. 2001. The clinical
onset of heparin is rapid. Anesth Analg. 92:1391–1395.
Hirsh J, Raschke R. 2004. Heparin and low-molecular-weight heparin: The
Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Chest. 126:188S–203S.
Jing W, DeAngelis PL. 2004. Synchronized chemoenzymatic synthesis of
monodisperse hyaluronan polymers. J Biol Chem. 279:42345–42349.
Linhardt RJ, Gunay NS. 1999. Production and chemical processing of low
molecular weight heparins. Semin Thromb Hemost. 25 Suppl 3:5–16.
Linhardt RJ, Liu J. 2012. Synthetic heparin. Curr Opin Pharmacol. 12:217–219.
Liu J, Shworak NW, Fritze LM, Edelberg JM, Rosenberg RD. 1996.
Purification of heparan sulfate D-glucosaminyl 3-O-sulfotransferase. J Biol
Chem. 271:27072–27082.
Liu R, Xu Y, Chen M, Weiwer M, Zhou X, Bridges AS, DeAngelis PL, Zhang
Q, Linhardt RJ, Liu J. 2010. Chemoenzymatic design of heparan sulfate
oligosaccharides. J Biol Chem. 285:34240–34249.
Merli GJ, Groce JB. 2010. Pharmacological and clinical differences between
low-molecular-weight heparins: Implications for prescribing practice and
therapeutic interchange. P T. 35:95–105.
Moon AF, Xu Y, Woody SM, Krahn JM, Linhardt RJ, Liu J, Pedersen LC. 2012.
Dissecting the substrate recognition of 3-O-sulfotransferase for the biosyn-
thesis of anticoagulant heparin. Proc Natl Acad Sci USA. 109:5265–5270.
Nightingale SL. 1993. Appropriate use of low-molecular-weight heparins
(LMWHs). J Am Med Assoc. 270:1672.
O’Leary TR, Xu Y, Liu J. 2013. Investigation of the substrate specificity of K5
lyase A from K5A bacteriophage. Glycobiology. 23:132–141.
Oscarsson LG, Pejler G, Lindahl U. 1989. Location of the antithrombin-binding
sequence in the heparin chain. J Biol Chem. 264:296–304.
Otto NJ, Green DE, Masuko S, Mayer A, Tanner ME, Linhardt RJ, DeAngelis
PL. 2012. Structure/function analysis of Pasteurella multocida heparosan
synthases toward defining enzyme specificity and engineering novel cata-
lysts. J Biol Chem. 287:7203–7212.
Pempe EH, Xu Y, Gopalakrishnan S, Liu J, Harris EN. 2012. Probing structural
selectivity of synthetic heparin binding to stabilin protein receptors. J Biol
Chem. 287:20774–20783.
Peterson S, Frick A, Liu J. 2009. Design of biologically active heparan sulfate
and heparin using an enzyme-based approach. Nat Prod Rep. 26:610–627.
Petitou M, Herault JP, Bernat A, Driguez PA, Duchaussoy P, Lormeau JC,
Herbert JM. 1999. Synthesis of thrombin-inhibiting heparin mimetics
without side effects. Nature. 398:417–422.
Petitou M, Lormeau JC, Choay J. 1991. Chemical synthesis of glycosaminogly-
cans: New approaches to antithrombotic drugs. Nature. 350:30–33.
Sheng J, Xu Y, Dulaney SB, Huang X, Liu J. 2012. Uncovering biphasic
catalytic mode of C5-epimerase in heparan sulfate biosynthesis. J Biol
Chem. 287:20996–21002.
Shively JE, Conrad HE. 1976. Formation of anhydrosugars in the chemical
depolymerization of heparin. Biochemistry. 15:3932–3942.
Shriver Z, Sundaram M, Venkataraman G, Fareed J, Linhardt R, Biemann K,
Sasisekharan R. 2000. Cleavage of the antithrombin III binding site in
heparin by heparinases and its implication in the generation of low molecular
weight heparin. Proc Natl Acad Sci USA. 97:10365–10370.
Chemoenzymatic synthesis of LMWH
485
Sismey-Ragatz AE, Green DE, Otto NJ, Rejzek M, Field RA, DeAngelis PL.
2007. Chemoenzymatic synthesis with distinct Pasteurella heparosan
synthases: Monodisperse polymers and unnatural structures. J Biol Chem.
282:28321–28327.
Xu Y, M S, Takieddin M, Xu H, Liu R, Jing J, Mousa SA, Lindhardt RJ, Liu J.
2011. Chemoenzymatic synthesis of homogeneous ultralow molecular
weight heparins. Science. 334:498–501.
Xu Y, Pempe EH, Liu J. 2012. Chemoenzymatic synthesis of heparin oligosac-
charides with both anti-Xa and anti-IIa activities. J Biol Chem. 287:
29054–29061.
Zhang Z, Weiwer M, Li B, Kemp MM, Daman TH, Linhardt RJ. 2008.
Oversulfated chondroitin sulfate: Impact of a heparin impurity, associated
with adverse clinical events, on low-molecular-weight heparin preparation.
J Med Chem. 51:5498–5501.
Zhao GH, Guan WY, Cai L, Wang PG. 2010. Enzymatic route to
preparative-scale synthesis of UDP-GlcNAc/GalNAc, their analogues and
GDP-fucose. Nat Protoc. 5:636–646.
Zhou X, Chandarajoti K, Pham TQ, Liu R, Liu J. 2011. Expression of heparan
sulfate sulfotransferases in Kluyveromyces lactis and preparation of
3′-phosphoadenosine-5′-phosphosulfate. Glycobiology. 21:771–780.
K Chandarajoti et al.
486
